Antibodies are a successful class of therapeutic agents ... Following the success of the first generation of monoclonal antibody blockbusters, second-generation antibodies were recently approved.

Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006 ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and ...

The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...

With an increasing understanding of the underlying pathogenetic mechanisms and identification of specific therapeutic targets, monoclonal antibody treatment has been an ideal strategy for inducing ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

Traditional methods for identifying therapeutic antibodies are not ... s Beyfortus (nirsevimab-alip), an anti-RSV monoclonal antibody approved for the prevention of RSV in infants.

Scientists have discovered a new type of anti-malarial antibody that doesn't interfere with current vaccines, at least in mouse models. Could they help eliminate malaria in the future?

Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, marking Ipsen's first ADC portfolio addition.United States, New York, Jan. 31, ...